Sun Pharma Names Former PwC India COO Satyavati Berera as Independent Director

The decision was taken by the company’s Board of Directors based on the recommendation of the Nomination and Remuneration Committee. The appointment will become effective upon approval by shareholders through a postal ballot.

Sun Pharma stated that the inclusion of Berera will strengthen the Board’s independence, governance standards, and overall expertise in oversight and decision-making, ensuring continued compliance with the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Satyavati Berera is a seasoned professional with over four decades of experience. She previously served as the Chief Operating Officer (COO) of PwC India and retired in 2023 after holding multiple leadership roles within the firm. She is an Economics graduate from Lady Shri Ram College, Delhi University, and a fellow member of the Institute of Chartered Accountants of India (ICAI).

She qualified as a Chartered Accountant in 1984 and became a Partner at Price Waterhouse in 1995. Over the years, she has held key positions including heading the consulting practice and serving as Managing Partner for the firm’s northern region. She also worked as an Audit Partner from 1995 to 2005.

Her professional experience spans assurance, consulting, governance, risk and compliance (GRC), as well as implementing control and process improvement solutions for domestic and multinational companies. Her tenure as COO provided her with deep expertise in finance, operations, human capital, technology, risk management, and regulatory compliance.

The company confirmed that Berera is not related to any director, key managerial personnel, or promoter of Sun Pharma and is not debarred from holding the office of director by any regulatory authority.

Also Read: Sun Pharma Rules Out Big-Bang Acquisitions, Bets on Organic Growth and Biosimilars